TP53 and colorectal carcinoma: Another study showed that the CHK1 inhibitor prexasertib (LY2606368) inhibited DNA replication and cell-cycle checkpoint activation in vitro and in vivo, leading to premature entry into mitosis and ultimately apoptosis in TP53-deficient CRC stem cells [81].